5865例IVF/ICSI-ET患者基础窦卵泡数预测卵巢储备功能的价值

目的:探索基础窦卵泡数(antralfolliclecount,AFC)预测卵巢储备功能的价值。方法:回顾性分析5865例应用长方案行IVF/ICSI-ET患者的临床资料。结果:①AFC与Gn用量呈非常显著负相关(r=-0.47,P<0.05),与成熟卵泡呈显著正相关(r=0.53,P<0.05)。②AFC预测卵巢反应不良率及妊娠率的ROC曲线下面积AUCl、AUC2值分别为0.86(95%CI=0.84～0.88)及0.56(95%CI=0.54～0.57),均显著大于参考值(P均<0.05)。并且,AUCl>AUC2,差异有统计学意义(Z=19.5,P<0.05)。③依据ROC曲线计算AFC预测卵巢储备功能的截断值为<10。AFC≥10组的Gn用量以及卵巢反应不良率均低于AFC<10组,差异显著(P<0.05);AFC≥10组的成熟卵泡数及妊娠率均高于AFC<10组,差异显著(P<0.05)。结论:AFC是一良好的评估卵巢储备功能的指标。且对于卵巢反应性的预测价值优于对IVF结局的预测。AFC预测卵巢储备功能的界定值为<10。     

抗苗勒管激素水平与卵巢反应性的相关性分析

目的:探讨育龄期女性抗苗勒管激素(AMH)水平与卵巢反应性的关系。方法:选择第一周期进行体外受精-胚胎移植(IVF-ET)治疗的患者1445例,在启动周期前采用酶联免疫吸附法(ELISA)检测患者血清AMH水平,用超声诊断仪检测卵巢窦卵泡计数(AFC),并结合年龄、体质量指数(BMI)等因素,计算其在卵巢低反应组(获卵数≤3个)和卵巢高反应组(获卵数>15个)的受试者工作特征(ROC)曲线下面积(AUC)。结果:Spearman相关及多元线性回归分析均显示,获卵数与AFC和AMH呈显著正相关(P<0.05),与年龄和方案选择呈显著负相关(P<0.05);多元线性回归分析示获卵数与BMI无明显相关性(P>0.05)。预测卵巢低反应时,AFC和AMH的AUC(分别是0.926和0.883)明显大于BMI和年龄的AUC(分别是0.454和0.181),AMH预测值为1.47μg/L,AFC的预测值为8个。预测卵巢高反应时,AFC和AMH的AUC(分别是0.764和0.759)明显大于BMI和年龄的AUC(分别是0.433和0.389),AMH的预测值为3.35μg/L,AFC的预测值为14个。结论:育龄期女性血清AMH水平与获卵数具有较强的相关性,能独立预测患者的卵巢反应性,且联合超声检测AFC可指导临床医生合理选择促排卵方案,获得优质胚胎,有效指导其生育。     

预测体外受精中卵巢反应性相关因素分析

目的:比较基础抑制素B(basal inhibin B,bINHB)、基础卵泡刺激素(bFSH)、年龄、窦卵泡计数(AFC)对于体外受精中卵巢反应的预测价值。方法:选取首次施行体外受精/卵胞质内单精子注射-胚胎移植(IVF/ICSI-ET)患者796例,于促排卵开始前1个月,测定月经第3日血清bINHB、bFSH水平,B超测定当日卵巢内AFC,分别比较其与获卵数的相关性。结果:bINHB、AFC与获卵数呈正相关性,相关系数(r)分别为0.147和0.661;bFSH、年龄与获卵数呈负相关,r分别为-0.239和-0.355,均P<0.001。按|r|值行相关性排序,bINHB、bFSH、年龄、AFC与获卵数相关性递增。结论:bINHB、bFSH、年龄、AFC均可以预测卵巢反应性,AFC是预测卵巢反应最好的指标。     

促性腺激素释放激素激动剂降调节后血清抑制素B水平对体外受精-胚胎移植结局的预测价值

目的 探讨促性腺激素释放激素激动剂(GnRH-a)降调节后,血清抑制素B(INHB)对体外受精-胚胎移植(IVF-ET)中卵巢反应性和IVF-ET结局的预测价值.方法 前瞻性观察124例行IVF-ET患者.超促排卵均采用GnRH-a+重组卵泡刺激素(rFSH)+人绒毛膜促性腺激素(hCG)黄体期长方案.观察指标:年龄、基础卵泡刺激素(bFSH)水平、卵泡刺激素(FSH)与黄体生成素(LH)比值、GnRH-a降调节后INHB水平、双侧卵巢内总窦卵泡数(AFC)及双侧卵巢体积.卵巢反应性评价指标为获卵数.通过多元线性回归分析、logistic同归分析评价各激素水平与卵巢反应性及IVF-ET结局的关系,计算受试者工作特征(ROC)曲线下面积(AUC),评价INHB水平预测获卵数的准确率,通过敏感度、特异度计算并确定其诊断临界值.结果 INHB水平与AFC呈显著正相关关系(r=0.435,P<0.01);多元回归分析显示,INHB水平与bFSH水平呈显著负相关关系(r=-0.239,P<0.01),与AFC(r=0.435,P<0.01)、获卵数(r=0.861,P<0.01)呈显著正相关关系,而与年龄、FSH/LH比值、卵巢体积无相关性(P>0.05).ROC曲线分析显示,GnRH-a降调节后,INHB水平的最大AUC为0.933(95%CI为0.878～0.988),将INHB水平为15 ng/L作为临界值时,其预测卵巢反应性的敏感度为95.5%,特异度为50.0%.结论 INHB水平足预测IVF-ET中卵巢反应性的最佳指标之一,INHB水平下降是卵巢储备功能下降的早期指标,但对IVF-ET结局无预测价值.     

不同年龄段不孕患者控制性超排卵中卵巢低反应的预测

目的研究不同年龄段不孕患者超排卵过程中卵巢低反应的发生情况,探讨不同年龄段患者卵巢低反应的相关因素及比较各预测指标的诊断价值。方法回顾性分析中山大学附属孙逸仙医院生殖医学中心2424个体外受精/卵细胞浆内单精子注射（IVF/ICSI）周期。按年龄分为4组,比较各组卵巢低反应的发生率及妊娠率;logistic回归分析基础FSH、基础LH、基础E2、窦卵泡数（AFC）、卵巢容积和BMI等与卵巢低反应的相关性,并根据回归结果计算联合指标的ROC曲线。结果 18～30岁组不孕患者卵巢低反应率为9.0%（77/852）,基础FSH与AFC联合预测卵巢低反应的ROC曲线下面积为0.726;31～35岁组卵巢低反应率为19.7%（172/871）,基础FSH、基础LH、AFC联合预测卵巢低反应的ROC曲线下面积为0.789;36～40岁组卵巢低反应率34.9%（190/545）,基础FSH、卵巢体积、AFC和年龄联合预测卵巢低反应的ROC曲线下面积为0.831;≥41岁组卵巢低反应率为69.2%（108/156）,AFC预测卵巢低反应的ROC曲线下面积为0.809。结论随着年龄增大,卵巢低反应发生率增加、妊娠率下降;不同年龄段预测卵巢低反应的指标不同,综合多指标的预测价值较单一指标预测价值高,建议综合多个有效指标评估卵巢的反应性。     

早卵泡期血清抗苗勒管激素水平在预测卵巢低反应中的价值探讨

目的:探讨早卵泡期血清抗苗勒管激素(AMH)水平对卵巢储备功能低下患者在控制性超排卵(COH)中预测卵巢低反应的应用价值及前景。方法:分析2013年10月至2015年6月在昆明医科大学第四附属医院接受体外受精/单精子卵母细胞内注射-胚胎移植(IVF/ICSI-ET)205个周期的患者,其中包括卵巢低反应患者70例(获卵数5个)和卵巢正常反应患者135例(15个获卵数≥5个)。在患者月经第二天或第三天清晨抽空腹静脉血,测定抗苗勒管激素(AMH)、基础卵泡刺激素(b FSH)、基础黄体生成素(b LH)及基础雌二醇(b E2)水平,同时行阴道B超检查测定窦卵泡数(AFC),以获卵数为评价标准。结果:年龄、AMH、AFC、b FSH及b FSH/b LH和获卵数存在相关性(P0.05),其中AMH相关性最强(r=0.597,P=0.000),其余相关性由强到弱为:AFCb FSH水平b FSH/b LH比值年龄。预测卵巢低反应ROC曲线下面积AMH最大,其余次序和相关性一致。预测卵巢低反应的AMH水平界值1.275μg/L(ROC曲线下面积0.823,灵敏度0.786,特异度0.852)。结论:血清AMH水平是反映卵巢储备能力的理想指标,可预测COH中卵巢低反应,用于指导临床选择合适的治疗方案。     

低剂量重组人促卵泡刺激素(rFSH)递增方案诱导排卵的多中心前瞻性研究

目的:探讨在低剂量重组人促卵泡刺激素(rFSH)递增方案诱导排卵中临床结局的预测因子。方法:总结全国22家生殖中心对WHO II型无排卵为主要不孕原因的患者使用低剂量rFSH递增方案共433个诱导排卵周期中418个符合疗效分析的周期的临床妊娠率、单卵泡发生率、周期取消率、卵巢过度刺激综合征(OHSS)发生率;比较37.5 IU和75.0 IU不同rFSH启动剂量的临床、实验室结局,分析单卵泡发育、卵巢诱导成功、周期取消与年龄、体质量指数(BMI)、卵巢储备等预测因子间的关系。结果:①所有对象临床妊娠率为17.94%,单卵泡发育率为57.66%,OHSS发生率为2.31%,多胎妊娠率为0.23%,周期取消率为12.68%;②果纳芬(rFSH)平均治疗天数为12.7±5.6 d,平均总使用剂量为813.8±480.4 IU,平均阈剂量为73.0±29.7 IU;其中75.12%的患者总使用剂量1 000 IU,73.68%的人群刺激天数在5~15 d之间;③启动剂量为37.5 IU者较启动剂量为75 IU者的卵巢诱导时间明显增加(14.1±5.6 d vs 10.9±4.9 d,P=0.000),果纳芬总使用剂量明显减少(767.0±495.0 IU vs879.1±542.7 IU,P=0.000),单卵泡发育率明显增加(62.30%vs 51.15%,P=0.027),周期取消率明显升高(17.62%vs 5.75%,P=0.000);OHSS发生率无明显差异(2.87%vs 1.72%,P=0.532),临床妊娠率和生化妊娠率亦无统计学差异(P0.05);④不同阈剂量下临床妊娠率和生化妊娠率均无统计学差异(P0.05);体质量≥70 kg时阈剂量明显增加;⑤周期取消的预测因素与年龄呈负相关(r=-0.169,OR=0.845,95%CI=0.744~0.960,P=0.010),与既往诱导排卵周期数呈正相关(r=-0.240,OR=1.271,95%CI=1.093~1.478,P=0.002)。结论:低剂量递增方案诱导排卵可以取得较高的单卵泡发育率和临床妊娠率,且降低并发症发生率。不同启动剂量与刺激天数和总使用剂量相关,但对临床结局无明显影响;周期取消可能与年龄和既往诱导排卵周期有关。     

ROC曲线评估移植前血清E_2、P水平和内膜厚度对FET结局的预测价值

目的通过监测冷冻胚胎解冻复苏移植(frozen embryos thawing recovery transfer,FET)前血清雌二醇(Estradiol E2)、孕酮(progesterone P)及内膜厚度,利用ROC曲线评价其预测妊娠结局的能力。方法回顾性分析2010年1月至2012年12月在内蒙古医科大学附属医院生殖中心行FET的临床资料,自然周期(组1)180例,激素替代周期(组2)187例,采用受试者工作特征曲线(ROC曲线)评估移植前日血清E2、P水平和内膜厚度对FET结局的预测价值,确定其临界值及最佳预测指标。结果比较两组血清E2和P及内膜的ROC曲线下面积与机会参考线下面积比较,对妊娠预测价值较低;而组1血清E2、P对流产的预测价值较高,ROC曲线下的面积分别为0.882和0.846,最佳临界值分别为204.4 pg/ml和18.15 ng/ml,均显著大于机会参考线下面积(P0.05)。结论移植前血清E2、P值及内膜厚度不能有效评估FET妊娠,对妊娠预测价值较低,但自然周期E2、P值对FET的妊娠结局流产的预测价值较高,两者可作为预测FET结局流产的参考指标。     

基础窦卵泡数在评价卵巢的反应性及预测人类辅助生殖技术(ART)结局中的作用

目的:探讨基础总窦卵泡数(tAFC)在评价卵巢功能和预测ART结局中的作用。方法:回顾性分析1 353例接受常规体外受精(IVF)/卵母细胞质内单精子显微注射(ICSI)治疗的不孕患者早卵泡期窦卵泡计数的资料,按tAFC分组:A组<5个,B组5~10个,C组11~15个,D组>15个,分别统计各组促性腺激素(Gn)用量、hCG注射日直径≥14 mm卵泡数、获卵数、2原核(2PN)数、可利用胚胎数及妊娠结局。结果:tAFC对卵巢反应性和卵巢储备功能的预测价值优于年龄和基础卵泡刺激素(bFSH),tAFC<10个预示卵巢低反应性,>12个则预示卵巢高反应性;tAFC对ART结局的预测价值稍优于年龄和bFSH,tAFC>10个则预示临床妊娠可能性大,tAFC>15个或<5个则预示周期取消率增加。新鲜周期妊娠率随tAFC增多而上升(C组最高42.3%),周期取消率随tAFC增多而下降,但tAFC>15个时,周期取消率上升至24.2%,主要原因是卵巢过度刺激综合征(OHSS)。结论:基础tAFC与影响ART结局的各种因素密切相关,可作为预测ART结局的参考指标,并且直接有效地评价卵巢储备功能和卵巢反应性,是患者接受ART前的首选检查,临床应用中值得推广。     

多囊卵巢综合征不孕患者未成熟卵泡抽吸术的疗效分析

目的:探讨对克罗米芬抵抗的多囊卵巢综合征(PCOS)不孕患者在超声引导下行小卵泡抽吸术(IMFA)的治疗效果。方法:将42例PCOS合并克罗米芬(CC)抵抗的不孕患者,随机分为A组:19例,穿刺前用CC或来曲唑(LE)联合少量hMG促排卵;B组:23例,穿刺前用少量hMG促排卵。在阴道B超引导下进行未成熟卵泡抽吸术(IMFA),观察穿刺前及穿刺后第2周期患者的卵巢基础窦卵泡数(AFC)、抗苗勒氏管激素(AMH)、血中游离睾酮指数(FAI)、黄体生成素与卵泡刺激素的比值(LH/FSH),以及术后并发症、3个月促排卵情况和妊娠率。结果:42例患者治疗时均没有发生卵巢过度刺激综合征(OHSS)。与治疗前比较,穿刺术后A、B组AFC显著减少,AMH、FAI和LH/FSH显著降低(P<0.01)。A、B组间比较,FAI、LH/FSH、排卵率和妊娠率无统计学差异(P>0.05)。A、B组共21例妊娠,妊娠率为50%。42例患者均没有发生出血、感染、OHSS。结论:IMFA治疗克罗米芬抵抗的PCOS不孕患者有较好的疗效,本方法安全、有效。     

Age,anti-müllerian hormone,antral follicles count to predict amenorrhea or oligomenorrhea after chemotherapy with cyclophosphamide

Background

A cohort study was performed to identify ovarian reserve markers (ORM) that predicts amenorrhea or oligomenorrhea 6 months after cyclophosphamide CTX in women with breast cancer.

Methods

52 eumenorrheic patients with breast cancer were enrolled. FSH, anti-Müllerian hormone (AMH), antral follicles count (AFC) were measured before and 6 months after CTX. A logistic regression for independent samples and determination of the ROC curve were performed.

Results

The age of 32 years presented 96 % of sensitivity and 39 % of specificity to predict amenorrhea or oligomenorrhea with ROC area under the curve (AUC) of 0.77. ovarian reserve marker (ORM) with power to predict amenorrhea or oligomenorrhea in women after CTX were AMH <3.32 ng/mL (sensitivity of 85 %, specificity of 75 % and AUC 0.87), AFC <13 follicles (sensitivity 81 %, specificity 62 %, AUC 0.81). AMH cutoff to predict amenorrhea was 1.87 ng/mL (sensitivity 82 %, specificity 83 %, AUC 0.84) and AFC cutoff was 9 follicles (sensitivity 71 %, specificity 78 %, AUC 0.73).

Conclusions

≥32-years-old women, AMH <3.32 ng/mL and AFC <13 follicles determined significantly higher risk of amenorrhea or oligomenorrhea after CTX with cyclophosphamide. The ORM age (≥32 years) analyzed together with AMH or AFC increases sensitivity and specificity in predicting amenorrhea or oligomenorrhea.

     

Antral follicle count determines poor ovarian response better than anti-müllerian hormone but age is the only predictor for live birth in in vitro fertilization cycles

Purpose

To determine the predictive value of serum anti-müllerian hormone (AMH) concentrations and antral follicle counts (AFC), on ovarian response and live birth rates after IVF and compare with age and basal FSH.

Methods

Basal levels of AMH, FSH and antral follicle count were measured in 192 patients prior to IVF treatment. The predictive value of these parameters were evaluated in terms of retrieved oocyte number and live birth rates.

Results

Poor responders in IVF were older, had lower AFC and AMH but higher basal FSH levels. In multivariate analysis AFC was the best and only independent parameter among other parameters and AMH was better than age and basal FSH to predict poor response to ovarian stimulation. Addition of AMH, basal FSH, age and total gonadotropin dose to AFC did not improve its prognostic reliability. Area under curve (AUC) for each parameter according to ROC analysis also revealed that AFC performed better in poor response prediction compared with AMH, basal FSH and age. The cut-off point for mean AMH and AFC in discriminating the best between poor and normal ovarian response cycles was 0.94 ng/mL (with a sensitivity of 70 % and a specificity of 86 %) and 5.5 (with a sensitivity of 91 % and a specificity of 91 %), respectively. However, age was the only independent predictor of live birth in IVF as compared to hormonal and ultrasound indices of ovarian reserve.

Conclusion

AFC is better than AMH to predict poor ovarian response. Although AMH and AFC could be used to predict ovarian response they had limited value in live birth prediction. The only significant predictor of the probability of achieving a live birth was age.     

抗苗勒管激素在辅助生殖技术中预测卵巢反应性的价值

目的:探讨抗苗勒管激素(anti-Mllerian hormone,AMH/MIS)在辅助生殖技术中预测卵巢反应性的价值。方法:按纳入标准选择80例第一次接受IVF-ET治疗的患者,于启动周期月经第2天用酶联免疫吸附法(ELISA)测定血清AMH水平;电化学免疫发光法测定基础血清FSH、LH、E2、T、PRL。同时用超声诊断仪为卵巢窦卵泡计数。记录促性腺激素总量、获卵数等。结果:(1)卵巢低反应组(n=14)与正常反应组(n=66)基础AMH水平分别为0.38±0.27ng/ml、2.10±1.25ng/ml,差异有统计学意义(P<0.05);(2)获卵数与基础血清AMH、窦状卵泡数(AFC)呈正相关,相关系数分别为0.776,0.577,与FSH、FSH/LH呈负相关,相关系数分别为-0.405,-0.528。多元线性回归分析各项指标对获卵数的影响按序依次为基础血清AMH、AFC、FSH、FSH/LH、年龄;(3)基础血清AMHROCAUC为0.961。卵巢低反应的基础血清AMHCut-off值为0.562ng/ml时,其灵敏度可达96%、特异性86%,阳性预测值92.3%,阴性预测值97%。结论:辅助生殖技术中基础血清AMH水平与目前临床常用指标相比,预测卵巢反应性的诊断价值最高,且灵敏、简便、经济。     

Is AMH useful to reduce low ovarian response to GnRH antagonist protocol in oocyte donors?

Abstract

We aimed to establish the reference values of Anti-Müllerian hormone (AMH) in our oocyte donor population and correlate them with the ovarian response to an antagonist stimulation protocol and to study the predictive capacity of AMH for poor response (PR). Normal AMH curves were obtained for 172 candidates. AMH levels decreased with age although they showed great heterogeneity and spread in absolute values at any age range. AMH levels showed a positive correlation, statistically significant, with the Antral Follicle Count (r?=?0,705), and number of oocytes retrieved (r?=?0,356). In receiver operating characteristic curve analysis a threshold value of AMH?=?2.31?ng/ml predictive for retrieval <6 MII (area under the curve (AUC) 0.675) was identified. This cut-off predicted PR with a sensitivity of 70.4% and a specificity of 61.8%, (PPV?=?39.6%; NPV?=?85.5%, p?=?0.004). When performing a multiple logistic regression analysis including age, AFC and FSH, an AUC?=?0.668 for PR was obtained whereas if AMH was added to the model it resulted in an AUC?=?0.713. In oocyte donors aged 18 to 35 with an AFC?≥?10 and basal FSH <10?mIU/ml, measuring AMH levels improved just slightly the prediction for PR.     

Follicular phase serum levels of luteinizing hormone do not influence delivery rates in in vitro fertilization cycles down-regulated with a gonadotropin-releasing hormone agonist and stimulated with recombinant follicle-stimulating hormone

OBJECTIVE: To assess the value of serum LH measurements in early and late follicular phase as predictors of ovarian response and IVF outcome in patients treated with recombinant FSH with GnRH agonist (GnRH-a) pituitary down-regulation. DESIGN: Retrospective cohort analysis. SETTING: Institutional. PATIENT(S): Women undergoing 157 consecutive IVF cycles suppressed with leuprolide acetate (LA) started in the midluteal phase and stimulated with recombinant FSH. Only women <40 years of age and with a basal cycle day 3 serum FSH 相似文献   

Role of baseline antral follicle count and anti-Mullerian hormone in the index stimulation cycle of IVF treatment in predicting outcome of subsequent frozen-thawed embryo transfers

This retrospective cohort study aims at determining whether baseline antral follicle count (AFC) and serum anti-Mullerian hormone (AMH) level in the index stimulation cycle predict live-birth outcome in subsequent frozen-thawed embryo transfer (FET) cycles. We studied 500 women undergoing the first IVF cycle who had embryo(s) cryopreserved. The main outcome measures were live-birth in the first FET cycle and cumulative live-birth in all the FETs combined after the same stimulation cycle. Our results showed that baseline AFC and AMH level on the day before ovarian stimulation showed significant correlation. In the first FET cycle, AFC and AMH level were significantly higher in subjects attaining live-birth in the first FET cycle or cumulative live-birth from all FETs than those who did not. Both AMH and AFC were insignificant predictors of live-birth in the first FET cycle or cumulative live-birth after adjusting for age. The areas under the ROC curves for AMH, AFC and age were 0.654, 0.625 and 0.628, respectively, for predicting cumulative live-birth. In conclusion, we reported for the first time that baseline AFC and AMH in the index stimulation cycle have only modest predictive performance on cumulative live-birth in subsequent FET cycles.     

Serum antimüllerian hormone measurements with second generation assay at two distinct menstrual cycle phases for prediction of cycle cancellation,pregnancy and live birth after in vitro fertilization

Purpose

This study investigated the usefulness of serum antimüllerian hormone (AMH) measurements at two distinct menstrual cycle phases to predict in vitro fertilization (IVF) outcomes.

Methods

This was a prospective observational study enrolling 135 consecutive patients referred for conventional IVF or ICSI in a university hospital. Blood samples were obtained for serum AMH measurements on days 3 and 18–20, while transvaginal ultrasound was performed for antral follicle count (AFC) at day 3 of the menstrual cycle immediately before treatment. AMH was measured with the new Beckman Coulter Generation II (GenII) assay. The main outcome measures were cycle cancellation due to poor ovarian response, clinical pregnancy, and live birth.

Results

There was a strong correlation between AMH levels measured at day 3 and day 18–20 of the menstrual cycle (r = 0.837; P < 0.0001). Day 18–20 serum AMH was comparable to day 3 serum AMH and AFC for the prediction of cycle cancellation (areas under the ROC curve were 0.84 for day 3 AMH, 0.89 for day 18–20 AMH, and 0.80 for AFC). Day 18–20 AMH had a modest predictive value for pregnancy or live birth (area under ROC curve 0.71 for both), which was comparable to that of day 3 AMH; however, AFC had no predictive value for these outcomes.

Conclusions

Day 18–20 AMH was comparable to day 3 AMH for the prediction of cycle cancellation, clinical pregnancy, and live birth after IVF. Both AMH measurements were accurate for the prediction of cancellation but were significantly less useful for the prediction of pregnancy or live birth.